What's new? Log in Free sign up

Telix Pharmaceuticals Limited (TLX)

Company Profile

Company profile

Ticker

TLX, TLPPF

Exchange

Website

telixpharma.com

CEO

Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

TLX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Current report (foreign)

Illuccix® Receives European Approval

Current Report of Foreign Issuer Pursuant to Rules 13A-16 and 15D-16 Amendments

Current Report of Foreign Issuer Pursuant to Rules 13A-16 and 15D-16 Amendments

Current Report of Foreign Issuer Pursuant to Rules 13A-16 and 15D-16 Amendments

Registration of securities for employees

Current report (foreign)

Current report (foreign)

Notice of effectiveness

SEC STAFF ACTION

SEC staff action: Order

Latest ownership filings

No filings

News

From Benzinga Pro

UBS Maintains Buy on Telix Pharmaceuticals, Raises Price Target to $22

UBS analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and raises the price target from $21 to $22.

ImaginAb Sells Therapeutic Pipeline, Technology Platform, And Research Facility To Telix; No Financial Terms Disclosed; Will Focus On CD8 ImmunoPET And Prostate Cancer Imaging In Phase 2 Trials

ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited ((ASX: TLX, NASDAQ:TXL).

SLB Posts Upbeat Results, Joins Bank OZK, Qorvo And Other Big Stocks Moving Higher On Friday

Telix Receives Positive Decision On Marketing Authorization Application For Its Prostate Cancer PET Imaging Agent Illuccix, Which Was Submitted In Europe

Reported Earlier, Telix To Acquire Imaginab's Drug Candidates And Cutting-Edge Antibody Engineering Platform For $45M

Press releases

From Benzinga Pro

Telix Completes Acquisition of RLS (USA) Inc.

MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS;

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has received a positive decision on the

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.